Catalan company INBRAIN Neuroelectronics, a member of Catalonia.health, has announced the completion of patient enrolment in its first-in-human study of graphene-based neural interfaces for brain decoding and mapping.

Catalan biotech company Aniling, a member of Catalonia.health, has announced a strategic collaboration with Illumina to advance unified genomic and epigenetic assays in oncology.

Catalan biotech company Sequentia Biotech, a member of Catalonia.health, has announced the achievement of CE-IVD marking under the new European IVDR regulation for its MICK Clinical™ solution, designed for gastrointestinal pathogen diagnostics.

Kymos Group, a European contract research organization specialized in services for the biopharmaceutical industry and a Catalonia.health’s member, has announced the acquisition of Particle Analytical ApS, a Danish company specialized in particle analysis and solid-state characterization.

Croda International Plc, a global leader in specialty ingredients and a Catalonia.health member company, has announced a strategic supply partnership with Amino GmbH, a leading manufacturer of pharmaceutical-grade amino acids, aimed at strengthening the global availability of high purity amino acids for pharmaceutical formulation and biomanufacturing.

Ysios Capital, a European venture capital firm specialized in life sciences and a Catalonia.health member company, has announced the launch of InceptionBio, a new fund with a target size of €100 million focused on biotech company creation and early-stage project development.

Catalonia.health is part of the AYRA project consortium, an industrial research initiative in digital health that is now entering its second phase with new clinical, technological and public health objectives.

The association participates in two meetings to consolidate strategic alliances within the Spanish and Catalan ecosystems.

This week featured two strategic meetings that strengthen the collaborative fabric of Spain's and Catalonia's biohealth sector.

Peptomyc has announced the closing of a €5 million financing round to support the next stage of development of OMO-103, its therapeutic candidate based on direct MYC inhibition. The financing strengthens the company’s clinical and industrial activity and supports continued progress in oncology.

Catalonia.health facilitates a direct dialogue between member CEOs and the Director General of AEI to explore ways to improve the relationship between the private sector and Spain's research administration.

Two strategic meetings this week have reinforced Catalonia.health's role as a global benchmark in health innovation. Catalonia's health ecosystem continues to attract interest from international actors seeking to learn from our model and establish valuable collaborations.

Eight Catalan companies from the health sector are participating in the first edition of this business growth program, which combines personalized mentoring and hands-on training.

Barcelona, February 27, 2026 – Catalonia.health participated this week in the fourth edition of the "Next Health: Life Sciences Innovation" conference series, co-organised with EY, focused on analysing how the Health & Life Sciences sector is generating tangible impact in sustainability. The event brought together experts from leading companies to share concrete examples of transformation and advances in this strategic area.

The technology center Eurecat, a Catalonia.health member, has incorporated a new technology called Olink® that analyzes up to 92 proteins simultaneously and accelerates the obtaining of results in advanced analysis of biological samples for the development of new products and services in sectors such as health, biotechnology, nutrition, and food.

The Germans Trias i Pujol Research Institute (IGTP), in collaboration with the Nephrology Service of Hospital Germans Trias and the spin-off Debios Diagnostics, all three members of Catalonia.health, are driving the PROMORFI project, a translational innovation initiative aimed at improving the detection and monitoring of chronic kidney disease through new non-invasive diagnostic tools.

Nema Health, a biotechnology company specialized in personalized immunotherapies for cancer treatment and a Catalonia.health member, has closed its first seed funding round. The operation totals €1.06 million, comprising a capital increase of €730,000 and a grant of €335,000 awarded by the CDTI's NEOTEC program (2025 call).

D-Sight, a clinical-stage spin-off from the Vall d'Hebron Research Institute (VHIR) and a Catalonia.health member, has secured €2 million in a new funding round led by Clave Capital, the company's main investor, to accelerate its clinical development plan in neuroprotective therapies for ocular diseases.

Catalonia.health has formalized the renewal of its Board of Directors and appointed Eva García Ramos as the new president of the organization at the General Assembly held in L'Hospitalet de Llobregat.

The University of Barcelona, a Catalonia.health member, has presented the strategic project VISI-ON-BRAIN (Cutting-edge Human In Vitro and In Silico Biomedical Tools on Brain Disorders), a European training and research program with €4.5 million in funding that connects UB with the best research centers in Europe.

Zymvol, a biotechnology company and a member of Catalonia.health, has announced a strategic collaboration with Olon, a global CDMO and generic manufacturer, to accelerate the adoption of biocatalysis as a scalable manufacturing solution for the pharmaceutical industry.